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Abstract The aberrant DNA methylation of the tumor sup-
pressor genes involved in DNA Damage Response (DDR) sig-
naling and cell cycle regulation may lead to the tumorigenesis.
Our purpose here is to analyze the promoter methylation and
mRNA expression levels of LATS1 and LATS2 (LATS1/2)
genes in OSCC. Promoter methylation status of LATS1/2 genes
was evaluated in 70 OSCC paraffin-embedded tissues and 70
normal oral samples, using Methylation Specific PCR (MSP).
LATS1/2 mRNA expression profiles were also investigated in
14 OSCC patients and 14 normal samples, using real-time
PCR. In both candidate genes, promoter methylation assess-
ment revealed significant relationship between cases and con-
trols (OR = 2.24, 95 % CI = 1.40–3.54, P = 0.001; LATS1 and
OR = 15.5, 95%CI = 3.64–64.76, P < 0.001; LATS2). As well
as, the evaluation of mRNA expression levels showed de-
creased expression in OSCC tissues in compare to control tis-
sues. (Mean ± SD 1.74 ± 0.14 in OSCC versus 2.10 ± 0.24 in
controls, P < 0.001; LATS1 and Mean ± SD 1.36 ± 0.077 in
OSCC versus 1.96 ± 0.096 in controls, P < 0.001; LATS2). To
the best our knowledge, this is the first report regarding the
down-regulation of LATS1/2 through promoter methylation in
OSCC. It is suggested to explore the down-stream transcription
factors of both genes for finding the molecular mechanism of
this deregulation in OSCC.
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Introduction
In developing countries, Oral Squamous Cell Carcinoma
(OSCC) is the most prevalent epithelial malignancy influenc-
ing the oral cavity (Parkin et al. 2001). OSCC accounts for
more than 90% of all oral neoplasms, therefore it is often used
interchangeably with oral cancer (Choi and Myers 2008). The
incidence rate of oral cancer is 1.08 and 1.25 per 100,000 in
men and women, respectively (Kordi-Tamandani et al.
2010a). Growth of OSCC is a multistep process, resulting
from a combination of genetic susceptibility and environmen-
tal risk factors including tobacco and alcohol consumption,
chronic inflammation and viral infection (Chien et al. 2013).
Oncogenes and tumor suppressor genes are the two major
groups of pro-tumorigenic genes which promote tumorigene-
sis whenever up-regulated or down-regulated, respectively
(Hanahan andWeinberg 2000). The down-regulation of tumor
suppressor genes is preceded through various epigenetic mod-
ifications, mutations, loss of heterozygosities and deletions
(Perez-Sayans et al. 2009). The epigenetic suppression of
genes take place through methylation of CpG islands or his-
tone modifications such as methylation of histone 3, lysine 27
(H3K27) (Rad et al. 2016).
Large Tumor Suppressor gene 1 (LATS1) and Large Tumor
Suppressor gene 2 (LATS2), which located on the 6q25.1 and
13q12.11 chromosomes, respectively; are key tumor suppres-
sor genes in the cell cycle regulation and DDR signaling
(Najafi et al. 2016). LATS1/2 localize to the mitotic apparatus
and regulate cell cycle through G2-M arrest and G1-S arrest,
respectively (Xia et al. 2002; Li et al. 2003). Novel Aurora A-
Lats1/2-Aurora B axis directs proper chromosome
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segregation and cytokinesis during mitosis (Yabuta et al.
2016; 2011). Also, these genes are main tumor suppres-
sors of hippo signaling pathway which has profound ef-
fects on normal cell fate and tumorigenesis (Aqeilan 2013).
Furthermore, in response to DNA damage, LATS1/2 serve
as tumor suppressor in Chk1-Lats2–14–3-3 and Chk1–
Lats2–p21 axes. Chk1-Lats2–14–3-3 regulates the P-body
formation in response to DNA damage and Chk1–Lats2–p21
axis facilitates apoptosis following high levels of UV
radiation, thereby both of the mentioned signals eliminate
damaged cells (Scrace and O’Neill 2012; Okada et al. 2011;
Suzuki et al. 2013).
Deregulation of LATS1/2 genes through methylation have
been examined in a number of malignancies such as lung
cancer, breast cancer, astrocytoma and colorectal cancer
(Sasaki et al. 2010; Jiang et al. 2006; Takahashi et al. 2005;
Wierzbicki et al. 2013). Our aim was to extrapolate the status
of LATS1/2 promoter methylation and mRNA expression
levels in OSCC patients.
Materials and methods
Subject
70 paraffin embedded tissues of OSCC (mean age
54.37 ± 14) and 70 oral mucosa biopsies as controls
(mean age 41 ± 14) were obtained from oral and dental
disease research center of Zahedan University of Medical
Sciences. All clinicopathological information of the pa-
tients and the controls filled out by pathologist. The insti-
tutional review board approved this study and all partici-
pants confirmed the consent form.
DNA extraction and modification
Genomic DNA was isolated from tumor and healthy tissue
samples as previously described (Kordi-Tamandani et al.
2010b). Sodium bisulfite modification was performed on
2 μg of DNA to treat un-methylated cytosine to uracil, while
leaving methylated cytosine unaltered according to the
Wizard® DNA Clean-Up System (Promega, Madison, WI).
Methylation-specific PCR (MSP)
Gene promoters were recognized through online ensemble
database. Then sequences of the considered genes were ap-
plied to design methylated and un-methylated primers, using
MethPrime online software (http://www.urogene.org/cgi-
bin/methprimer/methprimer.cgi).
1 μl of bisulfite-modified DNA and 0.5 μL of each
primer (10 mmol/l) were added to each AccuPower®
HotStart PCR PreMix tube (Cat. No. k-5050, Bioneer
Company) which contains lyophilized PCR master mix;
Taq DNA polymerase, dNTPs, reaction buffer, tracking
dye, and patented stabilizer, then the reaction reached to
a final volume of 20 μl using nuclease -free double-dis-
tilled water. MSP reactions were subjected to an initial
incubation 95 °C for 5 min, followed by 40 cycles (95 °C
for 40 s, the annealing temperature for LATS1: M = 53 °C,
U = 57 °C; LATS2: M = 55.5 °C, U = 55 °C for 40 s and
extension at 72 °C for 40 s). Final incubation was complet-
ed at 72 °C for 10 min. It should be pointed out that a
positive control (in vitro methylated and bisulfite-treated
human placenta DNA) and a negative control (no sample)
were incorporated in all reactions. The designed primers
were shown in Table 1.
Analysis of mRNA expression
Total RNA was extracted from fixed paraffin embedded
tissues, using the High Pure FFPE RNA Micro Kit) Cat
No: 04,823,125,001. As well as, isolation of total RNA
from fresh normal samples was performed, using Cinna
Pure RNA Purification Kit (Cat No: PR891620). cDNA
Synthesis Kit (Fermentas, Cat No: K1621) was utilized to
reverse-transcribe 1 μg of RNA to the cDNA in a final
volume of 20 μl. To evaluate the gene expression, the
Table 1 Methylation primer
sequences and annealing
temperatures
Genes Sequences (5′–3′) Annealing tem(°C) Product size
LATS1M F:GGAGTTT CGTTTTGTC
R: CGACGTAATAACG AACGCCTA 53 °C 138 bp
LATS1 U F: TAGGTTGGAGTGTGGTGGT
R: CCC AACATAATAACAAACACCT 57 °C 121 bp
LATS2M F: ATTTCGGTTTATTGTAATTTTC
R: AACCAACATAATAAAACCCCG 55 °C 148 bp
LATS2 U F: TTTGTTTTTT GGGTTTAAGT
R: CCAACATAATA AAACCCCA 55 °C 130 bp
M methyl, U unmethyl
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cDNA was amplified using specific primer (Table 2) and
SYBR green method in Applied Biosystems® 7500 ma-
chine (USA). The following optimal thermal condition
was applied: 10 min at 95 °C, 35 cycles of 15 s at 95 °C,
30 s at 57 °C, and 45 s at 72 °C. The real- time PCR data
was normalized by 18sRNA.
Statistical analysis
Statistical analyses were performed using SPSS version 23.0
(SPSS, IBM). Chi-square test was applied to analyze the cor-
relation between clinicopathological parameters and promoter
methylation status. Methylation status of LATS1/2 genes and
the risk of OSCC development through promoter methylation
were assessed using Logistic Regression. TheMann–Whitney
test compared mRNA expression data (CT target/Ct house-
keeping) between cases and controls. The p ≤ 0.05 was con-
sidered statistically significant.
Results
The promoter of LATS1/2 gene was methylated in OSCC
Our data revealed that the promoters of LATS1/2 were meth-
ylated in OSCC patients. The methylation frequency of
LATS1 gene was 26(37.14 %) in cases and 58(82.86 %) in
controls. LATS2 gene exposed 29(41.43 %) methylation in
cases and 58(82.86 %) in the controls. There was significant
association between methylation status of LATS1/2 genes and
the risk of OSCC development [LATS1: OR = 2.24; 95%CI:
1.40–3.54, p = 0.001, LATS2: OR = 15.5; 95%CI: 3.7–64.76,
p = 0] (Table 3).
Correlation between methylation statuses of LATS1/2
with clinicopathological data
There was significant correlation between gender and methyl-
ation status of LATS1 (p = 0.02). There was no correlation
between other clinicopathological data (age, gender and stage)
and methylation status of LATS1 and LATS2 (Table 4 and
Table 5, respectively).
Decreased mRNA expression levels of LATS1/2 in OSCC
patients
The mRNA expression Analysis of LATS1/2 genes in OSCC
relative to controls revealed the decreased expression of both
genes (1.74 ± 0.15 in case vs. 2.10 ± 0.24 in controls in LATS1
(p < 0.001)) and (1.96 ± 0.096 in cases vs. 1.31 ± 0.077 in
controls in LATS2 (p < 0.001)) (Table 6).
Discussion
A recent study has found reduced expression of DDR sig-
naling genes such as ATM,Mre 11 and H2AX in OSCC cell
lines (Wang et al. 2012). However, little is known about the
Table 2 Expression primer
sequences and annealing
temperatures
Genes Sequences (5′–3′) Annealing tem(°C) Product size
LATS1 F:GTTAAGGGGAGAGCCAGGTCCTT 60 °C 132 bp
R:TCAAGGAAGTCCCCAGGACTGT
LATS2 F:ACTTTTCCTGCCACGACTTATTC 60 °C 77 bp
R:GATGGCTGTTTTAACCCCTCA
18sRNA F:GTAACCCGTTGAACCCCATT 60 °C 112 bp
R:CCATCCAATCGGTAGTAGCG
Table 3 Risk of OSCC based on






OR 95%CI P value
LATS1 U(ref) 44(62.86 %) 12(17.14 %) 2.24 1.40–3.54 0.001
M 26(37.14 %) 58(82.86 %)
LATS2 U(ref) 41(58.57 %) 12(17.14 %) 15.5 3.7–64.76 0.001
M 29(41.43 %) 58(82.86 %)
OR odds ratio, 95% CI 95 % confidence interval, ref reference
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LATS1/2 genes in oral cavity cancers. The data of the
current study elucidated that DNA methylation mediates
reduction in mRNA expression levels of LATS1/2 in
OSCC patients.
LATS1/2 protein kinases control cell fate through different
signaling pathways (Yabuta et al. 2013). Overexpression
of LATS1 results in G (2)/M arrest through inhibiting the
CDC2 kinase activity, whereas LATS2 regulates G1/S
transition via modulating the kinase activity of Cyclin
E/CDK2 (Xia et al. 2002; Li et al. 2003). Furthermore,
at the onset of mitosis, LATS2 influences spindle forma-
tion to control precise segregation (Li et al. 2003). In
response to mitotic damage, LATS2 prevents damage
through inhibiting Mdm2, which in turn stabilizes p53
protein (Aylon et al. 2006). Another impressive role of
LATS2 in response to damage is apoptosis triggering




patients with OSCC and health
controls
Characteristics Control (n = 70) P Case (n = 70) P
Methylation status* Methylation status
M n(%) U n(%) M n(%) U n(%)
Age 0.97 0.76
> 50 48(82.8 %) 10(83.4 %) 22(84.6 %) 36(81.1 %)
< 50 10(17.2 %) 2(16.7 %) 4(15.4 %) 8(18.2 %)
Gender 0.03** 0.02**
Male 29(50 %) 10(83.3 %) 10(38.5 %) 29(56.9 %)
Female 29(50 %) 2(16.7 %) 16(61.5 %) 15(34.1 %)
Stage 0.11
I 12(20.7) 4(33.3 %)
II 17(29.3 %) 0(0 %)
Well differentiated 28(48.3 %) 7(58.3 %)
Metastatic 1(1.7 %) 1(8.3 %)
Chi-square test
*M methyl, U unmethyl
**significant




patients with OSCC and health
controls
Characteristics Control (n = 70) P Case (n = 70) P
Methylation status* Methylation status
M n(%) U n(%) M n(%) U n(%)
Age 0.97 0.5
> 50 48(82.2 %)) 10(83.3 %) 23(79.3 %) 35(85.4 %)
< 50 10(16.7 %) 2(17.2 %) 6(14.6 %) 6(20.7 %)
Gender 0.4 0.3
Male 31(53.8 %) 8(66.7 %) 14(48.3 %) 25(61 %)
Female 27(46.6 %) 4(33.3 %) 15(51.7 %) 16(38 %)
Stage 0.10
I 15(25.9 %) 1(8.3 %)
II 16(27.6 %) 1(8.3 %)
Well differentiated 26(44.8 %) 9(75 %)
Metastatic 1(1.7 %) 1(8.3 %)
Chi-square test
*M methyl, U unmethyl
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through phosphorylation of ASPP1 in Lats2-ASPP1-p53
axis which shunts p53 to pro-apoptotic promoters and
promotes apoptosis (Aylon et al. 2010). Unlike LATS2
gene, LATS1 gene achieves mentioned activities through
RASSF1A → MST2 → LATS1 pathway, which finally in-
duces apoptosis through blocking Mdm2 and leading to
p53 stabilization (Matallanas et al. 2011).
LATS1/2 on the hippo signaling pathway phosphorylate
YAP/TAZ dimer which leads to shift the dimer from cyto-
plasm to nuclear. Eventually, YAP/TAZ stimulate transcrip-
tion of TEAD factors which affect cell proliferation, me-
tastasis and epithelial-to-mesenchymal transition (EMT)
(Piccolo et al. 2014). Moreover, the phosphorylation of
LATS2 on Ser380 by Aurora A and its interaction with
Aurora B in ALB pathway (Aurora A-Lats1/2-Aurora B
axis) guarantee centrosome separation in response to mi-
totic signals. On the other hand, LATS2 could be phos-
phorylated on Ser83 by Aurora A which led to LATS2
centrosomal localization during interphase for centrosome
maturation. Intriguingly, after microtubule damage ALB
pathway prevents from aneuploidy through phosphoryla-
tion of Aurora B by LATS1/2 genes which form a tetra-
ploidy checkpoint together with P53 (Yabuta et al. 2016;
Furth and Oren 2011). Recently, Yabuta et al. (2016) re-
ported LATS1/2 phosphorylate inner centromere protein
(INCENP) at S894 which in turn activates Aurora B that
this is necessary for proper cytokinesis completion in
multipolar division (Yabuta et al. 2016).
LATS1/2 genes control cell cycle gates through above-
mentioned pathways; therefore their down-regulation
through promoter methylation could give rise to various
malignancies. Recently, it was demonstrated that reduced
mRNA expression levels of LATS1/2 genes result in de-
creased entry to the quiescence stage (G0) and increased
of cell growth (Sadasivam and DeCaprio 2013). In line
with this study, A number of articles displayed the down-
regulation of LATS1/2 genes through promoter methyla-
tion in different types of malignant and benign tumors
including lung cancer, human astrocytoma, breast cancer,
colorectal cancer and pterygium (Najafi et al. 2016;
Sasaki et al. 2010; Jiang et al. 2006; Takahashi et al.
2005; Wierzbicki et al. 2013). The status of LATS1/2
promoter methylation and mRNA expression changes
between these tumors has been summarized in Table 7.
Until now, previous studies have indicated the promoter
methylation and mRNA expression profiles of P14ARF,
MGMT, CDH1, APC, ATM, P15INK4b, P16INK4a,
FADD, FAS, ERK and RAF1 in OSCC (Kordi-Tamandani
et al. 2010b; Rigi-Ladiz et al. 2011; Kordi-Tamandani et al.
2012; Saberi et al. 2014; Kordi-Tamandani et al. 2014).
Taken together, the outcomes of the current study present-
ed novel methylation markers for designing drugs that
modify methylation statuses in OSCC (Mikeska and
Craig 2014).
In conclusion, our results showed the down-regulation of
LATS1/2 genes through methylation of their promoters. We
propose to use advanced molecular techniques such as
RNAseq in various genetic populations to identify the
down-stream transcription factors of both genes for exploring
the molecular mechanism of these deregulations in OSCC
(Zhang et al. 2013; Tuch et al. 2010).
Table 6 Comparison of relative gene expression for LATS1 and LATS2
genes between patients with OSCC and healthy controls
Genes No. Mean ± SD p-Valuea
LATS1 Cases 14 1.74 ± 0.15 0.001
Controls 14 2.10 ± 0.24
LATS2 Cases 14 1.31 ± 0.077 0.001
Controls 14 1.96 ± 0.096
aMann-Whitney-Test
Table 7 The contribution of
LATS1 and LATS2 promoter
methylation in different type of
malignant and benign tumors
Author Cancer Gene Promoter Methylation Expression
Takahashi et al. 2005 Breast* LATS1 17⁄30 (59/7 %) Decrease
LATS2 15⁄30 (50 %)
Jiang et al. 2006 Astrocytoma* LATS1 56⁄88 ( 63/66 %) Decrease
LATS2 63⁄88 (71/5 %)
Sasaki et al. 2010 Lung* LATS1 160⁄203 (78/8 %) Decrease
LATS2 95⁄119 (79/8 %)
Wierzbicki et al. 2013 Colorectal* LATS1 25⁄44 ( 57 %) Decrease
Najafi et al. 2016 Pterygium** LATS1 66⁄70 (94/28 %) Decrease
LATS2 69⁄70 (98/57 %)
*malignant
**benign
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